Roshan Abraham

Two, private equity-backed medical-device makers are the major contenders for North India-based BL Lifesciences, cloud platform Neysa is in talks for a larger round, Bajaj Finance has kickstarted its capital-raise process, and credit-management platform Oolka is in talks with investors that could double its valuation, according to several media reports.

BL Lifesciences

Healthium Medtech and Romsons Group are the key contenders to acquire about a 70-80% stake in Delhi-based medical-device maker and distributor BL Lifesciences, according to The Economic Times, citing sources. 
 
KKR-owned Healthium and Temasek-backed Romsons are the major contenders likely to value the fourth-generation family-owned business around Rs 1,800-2,000 crore (around $187-207 million), the report said. ET added that KPMG is advising the promoters on the stake sale. 

BL Lifesciences primarily focusses on products for cardiac surgery, critical care, interventional cardiology, anaesthesia and surgical care. Its portfolio spans perfusion systems such as heart-lung packs, oxygenators, cardioplegia sets; cath-lab kits, central venous catheters; invasive pressure-monitoring systems; and a broad range of surgical consumables including blood bags, instruments and wound-care products.

Neysa

Artificial intelligence (AI) cloud-platform Neysa is raising a $200 million (around Rs 1,929 crore) tranche led by Blackstone and other existing investors, according to a Mint report, citing sources. 

This is part of its larger $1.2 billion round with Blackstone investing close to $150 million, the report said. 

The remainder is expected to come from other investors including OTPP, TVS Capital, Nexus Venture Partners and 360 ONE Asset.

Bajaj Finance

Top private non-banking financial company Bajaj Finance has kicked off the preliminary work on a large capital raise of up to Rs 17,500 crore (around $1.8 billion) and picked three advisors, according to a Moneycontrol report, citing sources.

The fundraise, approved on October 2, is planned via a combination of a qualified institutional placement (QIP) of up to Rs 11,700 crore and a preferential issue of warrants for up to Rs 5,800 crore, according to the report.

Investment banks Kotak Mahindra Capital, JP Morgan and Morgan Stanley have been mandated and more advisors may be onboarded later, the report said. The company plans to launch the deal in November, preferably in the second half of the month, subject to market conditions.

Oolka

Credit-management platform Oolka is in advanced stages of raising around $45 million (about Rs 430 crore) in a fresh round of funding from Bessemer Venture Partners, Prosus and other existing investors, according to a Moneycontrol report, citing sources.

Bessemer is likely leading the round at Oolka with an investment of around $20 million and Prosus will pour in another $10 million. This would mark Oolka's second fundraise in about six months.

Existing investors such as Accel, Lightspeed, 8i Ventures and others are set to invest the remaining $15 million. Oolka's valuation has more than doubled to around $200 million (about Rs 1,900 crore) now during ongoing negotiations with Bessemer and Prosus, the report noted. It was last valued at around $90 million (about Rs 850 crore) in April 2026.

Two, private equity-backed medical-device makers are the major contenders for North India-based BL Lifesciences, cloud ......

Grapevine: BL Lifesciences, Neysa, Bajaj Finance, Oolka, others in news

General

Debjyoti Roy

Healthium Medtech, a KKR-backed medical device maker, is in advanced discussions to acquire a majority stake in a peer firm through a secondary transaction, at least two people familiar with the development told VCCircle.

Healthium, which focuses on products used in surgical, post-surgical and chronic care, has emerged as a leading contender to buy around 60% stake in Relisys Medical Devices, currently held by its early backer Siguler Guff, the people said. 

The deal size is likely to be around Rs 600-700 crore ($66-77 million). Detailed due diligence is currently underway, one of the persons said. 

A spokesperson for KKR & Co declined to comment, while email queries sent to Relisys and Siguler Guff remained unanswered till the time of publishing this article.

Siguler Guff had invested Rs 100 crore in Relisys in September 2021. The company had earlier raised its first institutional capital from healthcare-focused private equity firm InvAscent in 2015. InvAscent, which had also extended debt financing, exited Relisys in 2023.  

Founded in 1997, Relisys manufactures cardiovascular medical devices such as coronary stents and catheters. In 2018, it acquired stent manufacturer Multimedics to expand its global footprint. The company’s consolidated net sales increased to Rs 210 crore in FY25 from Rs 164.3 crore a year ago. Net profit, however, remained largely flat at around Rs 36 crore. 

Relisys’ founder, NK Reddy, is also a co-founder of Quality Care India Ltd, which operates hospitals under the CARE Hospitals brand. CARE Hospitals is now owned by Blackstone, which is in the process of merging the hospital chain with Mumbai-listed Aster DM Healthcare. 

Meanwhile, Healthium, launched in 1992, claims to be the world’s fourth-largest sutures manufacturer. The company has more than 85 registered patents, including pending applications, across the US, Europe and India, and operates in over 90 countries.

KKR acquired Healthium from UK-based Apax Partners in 2024 and had earmarked $150-200 million for acquisitions to scale the platform. In December last year, Healthium acquired a controlling stake in Paramount Surgimed, one of India’s largest manufacturers and exporters of surgical blades, scalpels and dermal biopsy products.

Healthium Medtech, a KKR-backed medical device maker, is in advanced discussions to acquire a majority stake in a peer ......

KKR-backed Healthium in advanced talks for controlling stake in smaller peer

surgery

Healthcare

Healthium Medtech, a KKR-backed medical device maker that is reportedly raising capital for acquisition-led expansion, has inked a deal to buy a controlling stake in a surgical products manufacturer to strengthen its surgical consumables portfolio.

The Bengaluru-based company will acquire a controlling stake in Paramount Surgimed Ltd. The financial terms of the deal were not disclosed.  

Founded in 1993, Paramount Surgimed manufactures, supplies and exports surgical blades, safety scalpels, skin graft blades, blood lancet, gouge blades, biopsy punch, among other products. The New Delhi-based company is led by Shaily Grover.

Healthium said Paramount's non-surgical businesses, including its lifestyle and hygiene businesses, will be carved out ahead of the transaction, with the Grover family retaining ownership of those businesses.

The acquisition will bolster Healthium's presence across surgical, post-surgical, arthroscopy, wound care and infection prevention categories, the company said in a social media post.  

For the financial year ended March 2025, Paramount Surgimed’s standalone revenue grew 9.6% year-on-year to Rs 122.6 crore compared with 22.4% growth in the previous year. Net profit rose 8.8% to Rs 6.4 crore in FY25, according to VCCEdge, the data research arm of VCCircle. 

Meanwhile, KRR, which last year acquired Healthium from UK-based Apax Partners, is said to have earmarked $150-200 million for acquisitions to scale up the medical devices maker. This is part of KKR's bolt-on strategy for which the US private equity major has allocated capital and resources.

Healthium Medtech, a KKR-backed medical device maker that is reportedly raising capital for acquisition-led expansion, ......

KKR-backed Healthium acquires controlling stake in surgical products maker

A clutch of homegrown private equity firms has joined the race to pick up a minority stake in Kerala-based in-vitro diagnostic (IVD) company Agappe Diagnostics, adding to the list of global rivals already evaluating the opportunity, according to at least two people familiar with the matter. 

The latest development comes after The Economic Times reported last month that global PE firms Warburg Pincus, TA Associates, Bain Capital, and CVC Capital were in early-stage discussions to acquire a stake in Agappe Diagnostics.

According to one of the people cited above, domestic PE firms ChrysCapital, Kedaara Capital and Motilal Oswal Alternatives (MO Alts) have now joined the discussions to pick up a stake in the company. 

The proposed deal is estimated to be worth around Rs 1,000 crore ($104 million), according to the second person. Agappe is likely to command a valuation of around Rs 3,000 crore, the person added.

Email queries sent to Agappe, ChrysCapital, Kedaara Capital and MO Alts remained unanswered till the time of publishing this article.

VCCircle had reported last year that Agappe was considering the dilution of a majority stake and had initiated early-stage discussions with a clutch of strategic investors backed by bulge-bracket private equity firms.

Founded in 1995, the company manufactures reagents and equipment for the in-vitro diagnostic industry. It has a network of over 1,000 distributors and claims a presence in over 90 countries. As per its website, it has a monthly production capacity of 400,000 reagent kits and 4,500 instruments per shift.

The company posted net sales of Rs 516 crore in FY25, up from Rs 442 crore a year ago. Profit after tax rose to Rs 31.2 crore from Rs 17.4 crore during the same period, according to VCCEdge, the data and research platform of VCCircle. 

The broader medical devices sector has witnessed a steady pace of dealmaking in recent months.

In February this year, VCCircle reported that KKR-backed medical device maker Healthium Medtech was in advanced discussions to acquire a majority stake in a peer through a secondary transaction.

In November last year, VCCircle also reported that PE-backed Entero Healthcare Solutions was set to acquire two companies engaged in the distribution of medical devices and healthcare products.

According to IMARC Group, the Indian medical devices market is expected to grow from $20.23 billion in 2026 to $31.85 billion by 2034, at a CAGR of 5.83%. Orthopedic devices accounted for the largest product segment in 2025 with an 18% share, while hospitals and ambulatory surgery centres represented 70% of end-user demand. South India led the regional market with a 34% share, driven by Tamil Nadu's healthcare ecosystem and Karnataka's medical device manufacturing base, the report said. 

A clutch of homegrown private equity firms has joined the race to pick up a minority stake in Kerala-based in-vitro ......

Homegrown PE firms join global rivals in race for stake in Agappe Diagnostics

US private equity firm KKR has agreed to acquire the India hospital business of Swedish healthcare provider Medicover AB in a deal valued at €1.2 billion (around $1.4 billion, or Rs 13,190 crore), strengthening its push to build a larger hospital platform in the country. 

This is KKR’s biggest healthcare deal in India and one of the largest across sectors in the country. The PE firm’s other large transactions in India include its 2020 deal to invest $1.5 billion (Rs 11,367 crore then) in Reliance Industries unit Jio Platforms Ltd and its 2024 acquisition of Healthium Medtech for about $810 million.

In the latest transaction, KKR will acquire 100% of Medicover Hospitals India, the hospital operations arm of the Stockholm-listed healthcare and diagnostic services provider, according to separate statements by the companies on Thursday. 

While KKR did not disclose the financial terms, Medicover said the transaction values the business at an enterprise value of €1.2 billion. Medicover owns 66.1% of the unit, while the remaining 33.9% is held by other shareholders.

KKR intends to eventually merge Medicover India and Baby Memorial Hospital, which it acquired in 2024, sometime in the future, creating a larger multi-speciality hospital platform, according to two people familiar with the matter. KKR’s oncology hospital chain Healthcare Global Enterprises (HCG), which the PE firm acquired last year, will continue to operate independently. "HCG will remain separate, but the other two (Baby Memorial and Medicover India) will be merged," one of the persons said, requesting anonymity. 

Queries sent to KKR and Medicover India remained unanswered till the time of publishing this article. 

At the agreed enterprise value, Medicover India is valued at 5.4x its last 12 months' revenue. The transaction will generate gross cash proceeds of €740 million for Medicover and support its growth strategy in Poland, Germany and Romania.

According to Medicover’s stock exchange filing, Medicover Hospitals India generated €220.5 million in revenue and €26.1 million in EBITDA over the last 12 months ended the second quarter of 2026. The business reported a preliminary EBITDA margin of 11.8% compared to the parent company’s 16.5%. 

Kotak Investment Banking advised KKR on the transaction.

Established in 2017, Medicover India is a multi-specialty hospital network with 24 hospitals and around 4,800 beds across south and west India. It offers comprehensive care across more than 80 clinical specialties, supported by more than 1,900 doctors. India contributed 14% of the Swedish firm’s revenue as of the second quarter of 2026. 

In December 2024, Medicover had said it was evaluating an initial public offering (IPO) of its India unit as a strategic alternative. However, the company later concluded that a sale transaction was the "superior" alternative for the unit and its shareholders.

“We are pleased to invest in Medicover India and look forward to contributing to its next phase by investing behind its talent, technology, infrastructure and clinical capabilities, while reinforcing strong clinical governance and operational standards," said Akshay Tanna, partner and head of India private equity at KKR.

KKR’s hospital play

KKR has been using Baby Memorial Hospital as a vehicle to acquire more hospitals in India. The firm had acquired a majority stake in Baby Memorial Hospital in 2024. The acquisition followed KKR's sale of its remaining stake in Max Healthcare in 2022 for around Rs 9,400 crore.

The Medicover acquisition adds to a series of buyouts by the firm in India's healthcare space. 

In early 2025, KKR struck a deal to acquire a controlling stake in HCG from CVC Capital. As part of the transaction, the firm agreed to acquire a 54% stake in HCG from CVC at Rs 445 per share, valuing the deal at Rs 3,428 crore ($400 million then).

In May this year, Baby Memorial Hospital acquired Hyderabad-based Star Hospitals to boost its regional presence. This was after VCCircle had reported in January that KKR was set to increase its stake in Baby Memorial Hospital, which would subsequently acquire a controlling stake in Star Hospitals. 

Last year, Baby Memorial Hospital also acquired Kerala’s Meitra Hospital and Tamil Nadu-based Naruvi Hospitals. In late 2024, it acquired Chazhikattu Hospital in Kerala’s Idukki district.

US private equity firm KKR said it will acquire the India unit of Swedish healthcare provider Medicover AB's ......

KKR expands India healthcare platform with $1.4 bn Medicover deal

Sreeja Biswas

US private equity giant KKR & Co. Monday announced an agreement to acquire Bengaluru-based medical device maker Healthium Medtech Ltd from UK-based private equity firm Apax Partners.  

The acquisition, slated to be completed in the third quarter of this year, will be facilitated through a special purpose vehicle owned by KKR-managed funds, it said in a joint statement with Healthium and Apax . 
 
KKR's Asian Fund IV will spearhead the investment, although specific financial details have not been disclosed.  

This move marks a significant triumph for KKR following an intense bidding war for Healthium, the country's second-largest surgical suture manufacturer. Notable contenders in the bidding process included a consortium of global private equity firms such as EQT (formerly BPEA EQT), Bain Capital, and Advent International, alongside Indian-focused firms like ChrysCapital and Mankind Pharma, as per reports.  

The acquisition by KKR comes on the heels of Healthium's unsuccessful attempt to launch a public offering. Additionally, in the financial year 2022-23, Healthium divested its UK-based business, the Clini group, specializing in the urology segment, to KKR.  

Formerly known as Sutures India Ltd., Healthium was acquired by Apax Partners from TPG and CX Partners in 2018. According to VCCEdge, the data research platform of VCCircle, the company reported a 11.2% growth in consolidated revenue to Rs 708.5 crore for the fiscal year ending March 2023. The company's consolidated net profit for FY23 surged to Rs 603.25 crore from Rs 79.3 crore in FY22, buoyed by a one-time gain from the sale of its UK business. 
 
The divestment of the Clini Group to KKR yielded proceeds of Rs 762.4 crore (post debt repayment of Clini Group) and a gain of Rs 490.3 crore for Healthium, VCCircle earlier reported.  

Jefferies LLC served as the financial adviser to Apax Partners and Healthium, with Kirkland & Ellis LLP providing legal counsel. Moelis & Co. acted as the financial adviser to KKR, with legal counsel provided by Simpson Thacher & Bartlett and AZB & Partners.  

Established in India in 1992, Healthium is a medical devices company specializing in the development, manufacturing, and global distribution of a diverse range of surgical products. Its product portfolio caters to various surgical specialties, offering solutions for wound closure, arthroscopy, and advanced wound care.  

Following Apax Partners' acquisition in 2018, Healthium significantly expanded its global footprint from 50 countries to over 90.  

US private equity giant KKR & Co. Monday announced an agreement to acquire Bengaluru-based medical device maker ......

KKR signs deal to acquire Healthium from Apax Partners 

Medical Devices

Medikabazaar, a business-to-business online marketplace for medical supplies, said Wednesday it has appointed Dinesh Lodha as the new group CEO. 

Lodha, the former group CEO of healthcare products supplier Healthium Medtech, has over two decades of experience in the medtech industry and has served in leadership roles across various sectors, Medikabazaar said in a statement.  

The appointment comes a month and a half after Medikabazaar co-founder Vivek Tiwari stepped down as the CEO following a PwC forensic audit report that revealed discrepancies in revenue recognition. Media reports at the time suggested that Medikabazaar might have overstated revenues from its medical equipment sales, its largest business segment. The alleged revenue manipulation could trigger clauses in the shareholder agreement, potentially reducing the co-founders’ equity stakes.  

Before joining Medikabazaar, Lodha served as the group CEO for TI Medical, a joint venture between Tube Investments and PremjiInvest, the family office of Wipro Ltd’s Azim Premji. His experience also includes roles at GE Healthcare and Samsung, where he managed their South Asia business.  

Lodha said that Medikabazaar was at an “inflection point” and that there were substantial opportunities across the verticals it operated in. “We will continue strengthening our collaborations with leading hospitals and healthcare professionals globally, serving as an extended procurement arm for all their medical procurement,” he said.  

Medikabazaar’s platform connects hospitals and clinics with manufacturers, distributors, and resellers of medical devices and supplies. The platform offers over 400,000 products and serves more than 10,000 medical centres and 30,000 independent doctors and clinics. The company has expanded its global presence over the years, targeting markets such as Dubai, Singapore, and China, and is exploring growth through acquisitions.  

The company was founded in April 2015 by Vivek Tiwari and Ketan Malkan. It last raised funding in April 2022, when it secured $65 million from investors. Private equity firm Lighthouse Funds led the round with a $30 million investment. Existing investors Creaegis, HealthQuad, Ackermans & van Haaren, British International Investment and KOIS Holdings also took part in the round. Previously, Medikabazaar raised $75 million in a Series C round in 2021 and $15 million in Series B financing in late 2019. 

Medikabazaar, a business-to-business online marketplace for medical supplies, said Wednesday it has appointed Dinesh ......

PE-backed Medikabazaar names former Healthium Medtech exec new CEO

People

Medical supplies manufacturer Healthium Medtech Pvt. Ltd has managed to improve its operating profit margins and is growing its revenue steadily but dividend payouts to help its controlling shareholder repay loans weigh on its prospects. 

The company, which was earlier known as Sutures India Ltd and was acquired by private equity firm Apax Partners from TPG in 2018, reported 11.2% growth in consolidated revenue to Rs 708.5 crore for the year through March 2023, according to VCCEdge, the data research platform of VCCircle. This was primarily led by healthy demand from key end-user industry segments for wound closure, both domestically and in export markets. 

Consolidated net profit for FY23 jumped to Rs 603.25 crore from Rs 79.3 crore in FY22, helped by a one-time gain on the sale of its UK business. Healthium sold its UK business, the Clini Group, to PE giant KKR. The transaction fetched the company proceeds of Rs 762.4 crore (post debt repayment of Clini Group) and a gain of Rs 490.3 crore. 

Total profit for FY23 from continuing operations, after excluding the UK business, increased to Rs 111.8 crore from Rs 73.3 crore the year before, according to the company’s disclosures. 

The sale of the UK business, increased revenue contribution from the high-margin wound closure products and improvement in the cost efficiency of the needles manufacturing facility pushed the company's EBITDA (earnings before interest, taxation, depreciation and amortisation) margin to 28.9% in FY23 from 23.3% in FY2022, according to VCCEdge. 

While a favourable product mix, new launches, strong volume growth and the sale of the relatively lower-margin UK business have aided Healthium Medtech in FY23, the company is slated to sustain this trajectory going ahead. 

It generated revenue of Rs 394 crore in the first half of FY24 and a net profit of a tad below Rs 70 crore, VCCircle has gathered. This puts it on track to achieve the pace of revenue growth posted last fiscal year and record a substantial jump in net profit for the full year.  

Healthium—one of the largest players in manufacturing needles and sutures for the domestic as well as global markets—exports its products to over 90 countries across Europe, South America, Africa and Asia. While it may have a large international operation on hand, the factor also poses certain risks to Healthium’s fundamentals going ahead.



Firstly, it faces competition on both domestic and international fronts from other large players like Johnson & Johnson, which is likely to restrict margins to a certain extent, ratings firm ICRA Ltd said in a report. 

Secondly, Healthium Medtech’s export market constituted 45% of its topline in FY23. While the company’s imports may provide a natural hedge to an extent, its profitability does remain subject to fluctuations in forex exchange movement.  

Another factor that weighs on the company is dividend payments to its owner, the PE firm Apax Partners. 

Healthium used the gains from the sale of the UK business to pay a dividend of Rs 640 crore to Apax last year and was likely to pay another Rs 80-90 crore before the end of the current fiscal year on March 31. Apax used the payouts to service the interest on the loan it had taken to acquire Healthium and help the company make some acquisitions. 

ICRA said it expects Healthium to keep paying Rs 80-90 crore dividend annually to Apax to help it repay the loan. That, and any debt-funded acquisitions, could put pressure on the company’s liquidity positing, the ratings firm said.

(Bottomline is a running series that captures the latest financials of startups and relatively bigger companies backed by alternative investors.)

Medical supplies manufacturer Healthium Medtech Pvt. Ltd has managed to improve its operating profit margins and is ......

Bottomline: PE-backed Healthium improves profit margins but dividend payouts weigh

K Amoghavarsha

Medical devices company, Healthium Medtech Ltd. (formerly Sutures India) is in the process of selling stake from its UK-based subsidiary, Clinisupplies to private equity major KKR. Financial details of the transaction were not disclosed. 

KKR will invest in Clinisupplies through its $4 billion Health Care Strategic Growth Fund II.

"The divestment of Clinisupplies is a strategic decision in-line with our business priorities and gives an impetus to our vision of facilitating precision medtech. We will continue to strengthen and expand our product portfolios in the surgical and post-surgical spaces," said Anish Bafna, chief executive officer and managing director, Healthium Medtech.
The Apax Partners-backed company plans to re-invest the proceeds from the transaction towards its portfolio in advanced surgery, wound care, orthopaedics, and post-surgical care. 

RBC Capital Markets was the lead financial adviser and Kirkland & Ellis the lead legal adviser to Apax and Healthium Medtech for this deal.

Based in Watford, UK, Clinisupplies was acquired by Healthium in 2016. The company has a strong portfolio of products in continence care and partners with the National Health Service (NHS) to supply continence care products. Healthium will continue to remain in the UK through its surgical consumables portfolio.

Healthium is a global medtech company focused on products used in surgical, post-surgical, and chronic care. It was acquired by Apax Partners in 2018 from existing shareholders including TPG Growth, CX Partners, and founding shareholders.  

As of 2022, it covers over 40,000 surgeons across 18,000 hospitals. It has a diverse portfolio of medical devices and consumables and holds 64 patents across the US, Europe, and India (including pending applications).  

Currently, the company has eight manufacturing facilities across India and also has a global presence with exports to over 80 countries, including the USA, France, Germany, and Brazil 

In 2021, Healthium made three acquisitions. It acquired AbGel on July 31, 2021. It also acquired VitalCare through a subsidiary Clinisupplies Limited for GBP 9.25 million (Rs.95.28 crore) in July.  In August 2021, it acquired CareNow for an initial purchase consideration of Rs.126 crore and a deferred consideration of Rs.5 crore. 

In November 2021, Healthium received the Securities Exchange Board of India’s (SEBI) approval for its initial public offering (IPO) and the size of the IPO was reported to be approximately Rs. 1,500 crore. 

Medical devices company, Healthium Medtech Ltd. (formerly Sutures India) is in the process of selling stake from its UK-......

KKR to buy stake in Apax Partners-owned Healthium Medtech\'s arm

Private equity firm Samara Capital is in advanced discussions to acquire a 50% stake in Del Monte Foods, a pasta and sauces maker, from Bharti Enterprises, a media report said.

Samara is also considering a minority stake in Godrej Tyson Foods, the producer of Yummiez frozen foods, with valuations for both the deal being discussed, The Economic Times reported, citing people aware of the matter. 
 
Both deals are expected to be integrated into a new $150 million roll-up platform focusing on packaged foods. Samara Capital established this platform in collaboration with a consortium of investors, including Convergent Finance LLP, an investment management and advisory fund. 
 
While negotiations with Bharti Enterprises for the Del Monte stake are progressing, discussions with Godrej Agrovet for the Godrej Tyson Foods stake are in preliminary stages, the report said.  

Novo Holdings

Novo Holdings, the controlling shareholder of the Danish diabetes and obesity drugmaker Novo Nordisk, has entered the race for Healthium Medtech, India's largest surgical sutures manufacturer and the world's largest producer of surgical needles, a media report said.

The entry of Novo Holdings is expected to further intensify the competition for Healthium, which has been valued by rival bidders in the range of Rs 6,500-7,000 crore. Currently, due diligence for the company is underway, The Economic Times reported citing people aware of the matter.

The move by Novo Holdings adds to the intense competition in the bidding process for Healthium, which is 99.8% owned by Apax Partners. Other contenders in the bidding process include buyout funds such as KKR, Hillhouse, EQT, Blackstone, and TA Associates.  
 
Novo Holdings had assets worth over $163 billion as of the last calendar year, with a portfolio of 170 companies. The firm primarily focuses on investments in life sciences and capital ventures, spanning equities, bonds, real estate, and infrastructure, alongside its holdings in the Novo companies.

INOXGFL Group

INOXGFL Group is planning a majority stake sale in its commercial and industrial business and has enlisted the services of EY for it, a media report said.

The transaction, which could potentially have an equity value of approximately $200 million, is still in its early stages, Mint reported, citing people aware of the matter. 
 
Devansh Jain, executive director of INOXGFL Group, had previously indicated that Inox Wind, a subsidiary focusing on wind energy solutions, intends to establish a commercial and industrial vertical primarily to meet the group's captive power demand, estimated at around 500-600 MW.

Private equity firm Samara Capital is in advanced discussions to acquire a 50% stake in Del Monte Foods, a pasta and ......

Grapevine: Samara in talks to buy Bharti\'s Del Monte stake; Healthium gets another suitor

VC_Desk_Section_Masthead

VC_Desk_Section_A_300x250

VC_Desk_Section_B_300x250

VC_Desk_Section_C_300x250

VC_Desk_Section_D_300x250

VC_Desk_Section_E_300x250

VC_Desk_Section_A_Skyscraper

VC_Desk_Section_B_Skyscraper

VC_Desk_Section_A_Billboard

VC_Desk_Section_B_Billboard

VC_Desk_Section_C_Billboard

VC_Desk_Section_D_Billboard

VC_Desk_Section_E_Billboard

VC_Desk_Section_Footer

Malvika Maloo

Private equity and venture capital investment activity improved this week, with both aggregate capital invested and deal......

Deals Digest: PE/VC funding value surges on Brookfield's bet

Reuters

Airtel Money shares fell below their offer price on Friday, in a muted start to trading for the African mobile ......

Airtel Money slips below IPO price in $7 bn London debut

Indian billionaire Mukesh Ambani's Jio Platforms is targeting a valuation of 10.3 trillion rupees ($106.48 billion) ......

Jio Platforms set to target nearly $106 bn valuation in IPO

Maverick Simulations Solutions Ltd, a provider of medical simulation and training products, is in advanced discussions ......

Medical simulator maker Maverick Simulations set to bag PE cheque, seal M&A deal

Economy

Global economic growth will likely slow to 2.6% in 2026, down from 2.9% last year, as the energy shock from ......

World economic growth to slow to 2.6% in 2026, UN trade body says

Prithvi Durai

Consumer

Mid-market private-equity firm Amicus Capital, which closed its second fund last year, has brought in co-investors for ......